The Spike protein, the main immunogen of this virus, displays a highly dynamic trimeric structure that presents a challenge for therapeutic development. Thus, protein-based immunogens that can quickly respond to viral changes remain of continued interest. Although early therapies such as prophylactic antibodies and vaccines show great promise, there are concerns about the long-term efficacy and universal applicability of these therapies as the virus continues to mutate. The worldwide pandemic caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is unprecedented and the impact on public health and the global economy continues to be devastating. 3Department of Inflammation and Oncology, Amgen Research, Amgen Inc., South San Francisco, CA, United States.2Department of Therapeutics Discovery, Amgen Research, Amgen Inc., South San Francisco, CA, United States.1Department of Therapeutics Discovery, Amgen Research, Amgen Inc., Thousand Oaks, CA, United States. Partin 1, Danqing Li 1, Danyang Gong 1, Zhulun Wang 2, Xinchao Yu 1, Paolo Manzanillo 3 and Fernando Garces 1* Riley 1, Hui-Ting Chou 2, Ruozhen Hu 3, Krzysztof P.
0 Comments
Leave a Reply. |
Details
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |